PaoliloRBHacohenYYazbeckE, et al. Treatment and outcome of aquaporin-4 antibody-positive NMOSD: A multinational pediatric study. Neurol Neuroimmunol Neuroinflamm2020; 7(5): e837.
2.
JacobAWeinshenkerBGViolichI, et al. Treatment of neuromyelitis optica with rituximab: Retrospective analysis of 25 patients. Arch Neurol2008; 65(11): 1443–1448.
3.
DaleRCBrilotFDuffyLV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology2014; 83: 142–150.
4.
HadjadjJGuffroyADelavaudC, et al. Progressive multifocal leukoencephalopathy in primary immunodeficiencies. J Clin Immunol2019; 39(1): 55–64.
5.
CarsonKREvensAMRicheyEA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: A report of 57 cases from the research on adverse drug events and reports project. Blood2009; 113: 4834–4840.
6.
VenetMLepineAMaaroufA, et al. Control of disease activity with large extended-interval dosing of rituximab/ocrelizumab in highly active pediatric multiple sclerosis. Mult Scler2024; 30(2): 261–265.
